http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020531573-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 |
| filingDate | 2018-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2020531573-A |
| titleOfInvention | Crystal form II of hydrogen sulfate of thienopyridine derivative, its production method and application |
| abstract | The present invention discloses crystal form II of hydrogen sulfate of a thienopyridine derivative, a method for producing the same, and uses thereof. The crystal form II has 12.86 °, 13.58 °, 15.58 °, 17.64 °, 18.42 °, 21.56 °, 22 in the X-ray powder diffraction pattern indicated by the 2θ diffraction angle. It has characteristic diffraction peaks at .90 °, 23.70 ° and 24.64 °. The crystalline form can produce a drug composition as an active ingredient and can be used for the prevention or treatment of diseases caused by thrombi. The crystalline form II of the present invention has better stability than the conventional crystalline form, and the solid granules in the subdivided package are more dense and less susceptible to static electricity, and have better fluidity and compressibility. , A drug composition can be produced as an active ingredient, the drug formulation having better stability. |
| priorityDate | 2017-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.